Search

Your search keyword '"Pan, Lili"' showing total 10 results
Start Over Author "Pan, Lili" Journal blood
10 results on '"Pan, Lili"'

2. Lncrna Famlf-2 Promotes Leukemogenesis Via the DHX9/c-Myc Axis in Acute Lymphoblastic Leukemia

Author

Lai, Xiaolin, primary, Cai, Yuanhua, additional, Huang, Yuanmao, additional, Shi, Shuiling, additional, Chen, Zhixiang, additional, Wang, Xuechun, additional, Tu, Fuquan, additional, Ye, Luya, additional, Li, Xiaofan, additional, PAN, Lili, additional, Li, Jinggang, additional, Li, Yang, additional, Gao, Huiying, additional, and Wang, Shaoyuan, additional

Published
2023
Full Text
View/download PDF

8. Homozygous CEBPAMutations Predict Favorable Outcomes in AML Patients

Author

PAN, Lili, Lin, Shenglong, Zheng, Yi, Ma, Yixin, Li, Yining, Xie, Yuwei, Cai, Yuanhua, Li, Xiaofan, and Wang, Shaoyuan

Abstract

Background:Loss of heterozygosity (LOH) of CEBPAhas been sporadically reported in acute myeloid leukemia (AML), resulting in a complete or nearly complete homozygosity of CEBPAmutations ( CEBPAhomo). However, its clinical significance has been underappreciated.

Published
2023
Full Text
View/download PDF

9. Clinical Features and Monitoring of Germline CEBPA-Mutated Carriers

Author

PAN, Lili, Li, Yining, Gao, Huiying, Cai, Yuanhua, Lai, Xiaolin, Chen, Zhixiang, Li, Xiaofan, and Wang, Shaoyuan

Abstract

Background:Despite being classified as an independent entity in World Health Organization (WHO) classification in 2016, familial cases of adult acute myeloid leukemia (AML) with germline-mutated CCAAT/enhancer-binding protein-α (CEBPA) gene have been rarely reported due to insufficient knowledge of the clinical features of this entity. Germline CEBPA-mutated carriers are at extremely high risk of developing AML but have long been ignored until the onset of AML. We aimed to fully identify the clinical features of the familial cases and healthy carriers for this entity to call for a guideline for its management.

Published
2023
Full Text
View/download PDF

10. Targeting G3BP2 Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment Via ELF1-MCL1 Axis

Author

Chen, Zhixiang, Cai, Yuanhua, Lai, Xiaolin, Wang, Xuechun, Yan, Xiongbin, Wang, Yaping, Tu, Fuquan, Wu, Wanting, Li, Yang, Pan, Lili, Zheng, Yi, Li, Jinggang, Li, Xiaofan, and Wang, Shaoyuan

Abstract

Venetoclax-based combination therapies have emerged as promising treatments for elderly acute myeloid leukemia (AML) patients. However, venetoclax resistance renders the treatment ineffective, mainly due to the upregulation of MCL1. Thus, new venetoclax-based combination therapy is under development to circumvent venetoclax resistance. The Ras-GTPase-activating protein SH3-domain binding protein 2 (G3BP2) is upgraded in several solid tumors. Targeting G3BP2 re-sensitized tumor cells to chemotherapy. To date, whether targeting G3BP2 sensitizes venetoclax treatment in AML and its role in leukemogenesis has not been defined.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results